Nov 4, 2026
New York, November 4, 2026 -- The company establishes a defined molecular specification and analytical development pathway for Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-Adam-NH₂.
NEW YORK, November 3, 2026 — Uther Peptide today announced progress in the research and synthesis development of an adamantane-modified Adalank research reagent, establishing a defined structural specification centered on the sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-Adam-NH₂. The development program marks a new step in the company’s research-reagent platform, with emphasis on exact molecular structure, synthesis methodology, batch identity, and analytical verification before routine research production.

Moving Beyond an Ambiguous Product Name
Uther Peptide says one of the primary objectives of the project is to reduce ambiguity surrounding the name “Adalank.” Publicly available research-chemical references do not always use a consistent structural definition for the term. For its development program, Uther Peptide therefore defines the target research reagent through its explicit structural designation rather than relying solely on a commercial product name.
Target research structure: Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-Adam-NH₂
A Structure-Defined Development Strategy
The core peptide sequence is based on the seven-residue framework Thr-Lys-Pro-Arg-Pro-Gly-Pro, with an N-terminal acetyl modification and a defined adamantane-derived terminal modification incorporated into the research design. The structure-defined approach is intended to distinguish the target material from research products that may use similar names while containing different chemical modifications.
Development of the Synthesis Pathway
Uther Peptide’s synthesis-development work is based on a controlled peptide-assembly process designed to construct the defined amino-acid sequence in the required order before introducing the specified structural modifications. At a high level, the development pathway includes protected peptide-chain assembly, sequence completion, N-terminal acetyl modification, adamantane-derived structural modification, cleavage and deprotection, purification, analytical identity confirmation, lyophilization, and batch documentation.
The company says the purpose of the development stage is not simply to produce material, but to establish a repeatable synthesis and analytical process capable of distinguishing the intended molecular construct from incomplete sequences, deletion products, and other synthesis-related impurities. Exact manufacturing parameters remain part of Uther Peptide’s internal production specifications.
Analytical Identity Is Central to the Project
Uther Peptide says analytical characterization is especially important for modified peptides because a product name alone cannot establish the identity of the material contained in a vial. The Adalank development program therefore places particular emphasis on confirming that the final research material corresponds to the intended structure.
Analytical evaluation may include chromatographic purity analysis, molecular-mass confirmation, and other structural characterization appropriate to the development stage. Uther Peptide also links batch-specific third-party analytical records to the relevant research batch.
The current Adalank batch documentation includes Purity & Quantity Data, Endotoxin Data, and Heavy Metals Data, each hosted on the independent laboratory’s own verification domain.
The company’s objective is to establish a direct relationship between defined structure, production batch, analytical identity, purity and quantity data, endotoxin data, heavy-metals data, and published batch documentation.
Why the Adamantane Modification Matters From a Chemistry Perspective
Adamantane-derived groups are used in medicinal and peptide chemistry as structural modifications because their rigid, hydrophobic framework can alter the physicochemical characteristics of a molecule. Uther Peptide emphasizes, however, that incorporating an adamantane-derived modification into a peptide creates a chemically distinct research construct.
For this reason, data generated for unmodified Selank or for differently modified Selank analogues cannot automatically be treated as data for the adamantane-modified Uther research sequence. The modified material must therefore be characterized as its own analytical research reagent.
Separating Chemical Development From Biological Claims
Uther Peptide emphasizes an important distinction between chemical development and biological or clinical claims. The current development program focuses on chemical identity, synthesis reproducibility, batch consistency, and analytical characterization. Any biological properties of the modified structure would require independent experimental investigation.
Establishing a More Precise Standard for Emerging Research Peptides
Uther Peptide says the Adalank project reflects a broader evolution in its research-product development strategy. As increasingly complex modified peptides enter the research market, the company intends to rely less on commercial product names and more on explicit structural specifications.
Under this approach, a research reagent should be defined by its sequence, its chemical modifications, its analytical identity, and its batch-specific documentation. The company believes this framework is particularly important when the same research name is used for more than one molecular design.
From Molecular Design to Batch Verification
The Adalank development project follows a structured workflow: Molecular Design → Sequence Definition → Synthesis Development → Structural Modification → Purification → Analytical Characterization → Batch Standardization → Independent Testing → Research Documentation.
Uther Peptide says the objective is to establish a reproducible, traceable, and analytically defined research reagent rather than relying solely on a commercial name or theoretical structure.
Research Use Only
The Uther Peptide Adalank development material is intended strictly for laboratory, analytical, and scientific research. It is not intended for human consumption, self-administration, diagnosis, therapeutic use, or clinical treatment. Uther Peptide makes no claim that biological, pharmacological, or clinical findings associated with Selank apply to the adamantane-modified research structure described in this release.
About Uther Peptide
Uther Peptide is a research-focused peptide and biotechnology brand supporting laboratory, analytical, and scientific research applications across multiple international markets. The company focuses on structure-defined research-product development, manufacturing transparency, batch traceability, independent analytical testing, and batch-specific documentation. Official website: utherpeptide.com
Contact Info:
Name: Turalyon
Email: Send Email
Organization: Uther Peptide
Website: https://utherpeptide.com/
Release ID: 89208403
In the event of encountering any errors, concerns, or inconsistencies within the content shared in this press release, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your feedback within 8 hours and take appropriate measures to rectify any identified issues or facilitate press release takedowns. Ensuring accuracy and reliability are central to our commitment.
What was teased for weeks as an unprecedented three-way photo opportunity ended up rattling the geopolitical landscape on Thursday with the release of a China-US-Russia joint “peace declaration” outlining areas of cooperation in worldwide energy markets, nuclear non-proliferation and global governance. At the conclusion of the first-ever three-way meeting in Shenzhen between Chinese President Xi Jinping, US President Donald Trump and Russian President Vladimir Putin, the trio issued a statement...
India's Permanent Representative to the United Nations, Parvathaneni Harish, addressed Pakistan's military at a recent UN meeting. He emphasized the need for Pakistan's military to use natural resources for public benefit instead of personal gain. Harish highlighted the military's exploitation of resources and its impact on political stability, particularly mentioning the dismissal of the Khyber Pakhtunkhwa government.
Starting in 2027, eligible workers can receive a federal contribution for retirement savings based on their contributions. The Saver's Match, created by the SECURE 2.0 Act, replaces the Saver's Credit after 2026. Workers contributing up to $2,000 can receive a match of 50% from the federal government. Eligibility criteria include income limits and not being someone else's dependent or qualifying full-time student.
The Supreme Court addressed the limitations of the Election Commission in controlling booth-level agents' actions. The ruling came during a case concerning fraudulent objections to voter deletions in Delhi's Mustafabad. Allegations were made that several Form 7 objections were filed without authorization from the listed agents. The Chief Justice remarked that the Commission can only blacklist agents involved in such fraudulent activities.
Assam Medical College and Hospital issued an advisory advising postgraduate trainees to delay personal milestones, including marriage. The United Doctors Front criticized this advisory as an undue pressure on residents' personal lives. Following this backlash, the medical college withdrew the advisory to avoid further controversy. Residents in their late 20s or early 30s expressed concerns over such restrictions impacting their personal choices.
India and Japan have signed a letter of intent to allow Japanese forces to conduct live-fire training in India. This training includes the use of surface-to-ship missiles for the first time on Indian soil. The recent 2+2 Ministerial Meeting in Tokyo highlighted the expansion of military exercises and cybersecurity cooperation. Efforts will also focus on space cooperation and maritime security amidst regional tensions.
National Testing Authority plans to introduce Computer Based Testing for NEET-UG in 2027. They aim to prepare candidates by offering practice sessions at test centers and through the Abhyas app. The initiative will particularly focus on aiding students from rural areas to address the digital divide. A significant challenge involves creating a large question bank of over 20,000 questions.
The Punjab and Haryana High Court has stayed the recruitment process for Punjab Civil Services due to serious allegations. Several petitions have been filed that claim significant irregularities in the selection process. The petitioners argue that multiple roll numbers were issued to candidates, violating recruitment guidelines on gender and categories. Additionally, issues regarding age criteria and language qualifications are also being questioned in the petition.
Vijay Sankar has officially taken over as the president of FICCI for its centenary year, which is 2026-2027. Sankar is the chairman of the Sanmar Group, a significant player in chemicals and engineering sectors. Puneet Dalmia has been promoted to senior vice president, reflecting the evolving leadership within the organization. Additionally, Shreevar Kheruka has joined FICCI's leadership team as vice president.
AMD stock crashes 11% after Hunterbrook's China allegations. After Jensen Huang's Nvidia, Lisa Su's AMD faces export-control questions. The controversy comes at a sensitive time for AMD's business. China and Hong Kong accounted for approximately $7.75 billion, or 22.4%, of the company's fiscal 2025 revenue. Singapore accounted for another 12.4%. Here's the complete picture why AMD shares are falling today.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.